Endocrine Society Recommendations on How to Avoid Hypoglycemia in Patients with Diabetes: A Guideline Topline

The Endocrine Society's updated 2023 clinical practice guideline for managing individuals with diabetes at high risk for hypoglycemia emphasizes the value of continuous glucose monitoring (CGM) and algorithm-driven insulin pumps; and recommends treatment with long-acting insulin analogs rather than NPH human insulin in basal insulin therapy, and short-acting insulin analogs rather than short-acting human insulin in basal-bolus therapy.

The new 10-recommendation guideline is the first update since the 7-recommendation guideline of 2009 and was necessary to incorporate recommendations on advances in technologies and therapeutics, including new formulations of glucagon, and technology-driven inpatient glycemic surveillance and management programs.

Click through the short slideshow here for a Guideline Topline of Management of individuals withdiabetes at high risk for hypoglycemia: an Endocrine Society Clinical Practice Guideline.